@entity4611 following cranial radiotherapy for adult-onset XXXX .

@entity1 @entity4089 @entity1220 @entity1313 @entity5 @entity16054 @entity51 @entity4614 @entity4611 @entity7961
OBJECTIVE: There are limited data concerning the evolution of radiation-induced @entity4614 in adult-onset @entity1313 (AO-BT) survivors; in part the consequence of the limited survival of many of these individuals. We aim to characterise the pituitary-related outcomes following cranial radiotherapy (cXRT) for adult-onset primary @entity1313 . DESIGN: We retrospectively analyzed longitudinal data of @entity1 with AO-BT who received cXRT within a tertiary @entity5 referral center. @entity1 : 107 adults (age 40.0  13.1 years) followed for a median duration of eight years following cXRT. MEASUREMENTS: Prevalence of radiotherapy-induced @entity4614 . RESULTS: 94.4% received fractionated photon radiotherapy (median dose 54Gy), while the remaining @entity1 received proton beam or stereotactic radiotherapy. 88.8% of @entity1 developed @entity4614 during follow-up. The frequency of GH, gonadotropin, ACTH and @entity1220 was 86.9% (severe GHD 64.5%, partial GHD 22.4%), 34.6%, 23.4% and 11.2% respectively. @entity16054 was clinically significant, necessitating glucocorticoid replacement, in only 10.3% of cases. @entity4089 developed in 15% of @entity1 , which was persistent in only 50% of cases. @entity7961 were present in 47.7% of @entity1 ; encountered more frequently in @entity1 with @entity5 in proximity to the sella. Longitudinal data analysis revealed @entity51 throughout the follow-up period, with incidence of all @entity7961 almost doubling between years 2 and 7 of follow-up. CONCLUSIONS: @entity4611 in AO-BT survivors following cXRT is a common, evolving, time-dependent phenomenon. It is important deficits are identified early and replacement therapies introduced to optimize quality of life in these individuals, where prognosis is often guarded. This article is protected by copyright. All rights reserved.
